Skip to content
OpenCapital
Get started

TriSalus Life Sciences, Inc. TLSI Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

InfuSystem Holdings logo
InfuSystem HoldingsINFU
——

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%—
Debt / equity2.6×—
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s amortization expense related to capitalized debt issuance costs?
TriSalus Life Sciences, Inc. (TLSI) reported amortization expense related to capitalized debt issuance costs of $296K in Q1 2026.
How has TriSalus Life Sciences, Inc.'s amortization expense related to capitalized debt issuance costs changed year-over-year?
TriSalus Life Sciences, Inc.'s amortization expense related to capitalized debt issuance costs increased by 26.0% year-over-year, from $235K to $296K.